A Phase 1/2, Randomised, Placebo-controlled, Double-blind, Multi-centre Study to Evaluate the Efficacy and Safety of OC5 to Reduce Urinary Oxalate in Subjects With Primary Hyperoxaluria
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Lyophilised Oxalobacter formigenes (Primary)
- Indications Primary hyperoxaluria
- Focus Therapeutic Use
- Sponsors OxThera
- 27 Apr 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 04 Sep 2014 Planned End Date changed from 1 Jul 2014 to 1 Jan 2015 as reported by ClinicalTrials.gov record.
- 04 Sep 2014 Planned primary completion date changed from 1 Jul 2014 to 1 Jan 2015 as reported by ClinicalTrials.gov record.